**104** Poster

**Effects of androgen and valproic acid treatment on androgen-dependent cell line (LnCaP-SF)**

A. Valentini[1], C. Stellitano[1], P. De Vita[1], S. Bernardini[1], G. Federici[2]
*[1]PTV-Università di Roma "Tor Vergata", Internale Medicine and Laboratory Medicine, Roma, Italy; [2] PTV-Università di Roma "Tor Vergata", Internale Medicine and Laboratory Medicine and Bambino Gesu` Children's Hospital-IRCSS, Roma, Italy*

Prostate carcinoma (PCa) originates as an androgen-dependent hyper-proliferation of the epithelial cells of the gland and it evolves in an androgen-independent, highly aggressive cancer for which no cure is available to date. Studies in the last two years have corroborated that the short chain fatty acid valproate (VPA) potently modulates the biology of prostate cancer cells by inducing differentiation, inhibiting proliferation and increasing apoptosis. Hence we studied the effect of VPA in combination with dihydrotestosterone (DHT) on the human prostate cancer cell line, LNCaP-SF.

LNCa-SF is an androgen-deprivation induced human prostate cancer cell line, generated from the androgen-sensitive LNCaP cells, cultured in RPMI-1640 media containing charcoal-stripped FBS for a prolong period (more than four months). LNCaP-SF cells express considerably lower levels of androgen receptor than LNCaP cells and grow faster in androgen restricted condition in vitro.

In the human prostate cancer androgen-dependent cell line (LnCaP-SF) the responsiveness to androgen and valproic acid in vitro was exanimate, we observed that VPA was able to down-regulate both AR gene and protein expression, decreasing PSA levels, even in DHT presence. Moreover, LNCaP-SF proliferation was inhibited by VPA treatment of about 45%, with the G1 phase arrest (70%) and induction of apoptosis (29%). In addition we observed that after 72 hours of VPA (2 mM) treatment, cells switched into oblong cells with long dendritic processes losing the rounded up phenotype.

The hormones homeostasis, hence steroids metabolism, in prostate is guaranteed by UGTs which glucuronidate DHT metabolites through an irreversible process. Because VPA is it same a substrate of UGTs, we investigate the effect of VPA on some UGTs expression.

We found that VPA treatment modulates expression of such enzymes (UGT2B7, UGT2B11, UGT2B15) in LNCaP-SF cells, hence we cannot exclude a competitive effect of VPA in steroid catabolism. Although, VPA can reduce PSA and AR expression, decreasing cell proliferation rate, the action of VPA on prostate cancer should be further investigated. Therefore, in view of VPA ability in modulate hormone homeostasis of prostate cancer, LNCaP-SF cell line results a valuable tool for studying its molecular mechanisms.

**105** Poster

**Synergistic activation of JAK/STAT and NF-kB pathways by GMCSF/IL2 fusion protein induces robust NK cell proliferation and activation**

C. Penafuerte[1], J. Galipeau[1]
*[1]Jewish General Hospital, Medicine, Montreal - Quebec, Canada*

NK cells constitute a potential candidate for cancer cell therapy because they express a diverse array of inhibitory and activating receptors, which recognize and kill infected cells or tumor cells without prior immune sensitization. However, autologous NK cell mediated adoptive immuno-therapy is restricted due to insufficient cytolytic activity of NK cells from patients with aggressive malignancies. In contrast, the infusion of alloreactive NK cells has shown more successful outcomes in the treatment of cancer, but this approach also presents difficulties such as the high doses of cytokines required to induce NK cell expansion ex vivo, which may also sensitize NK cells to apoptosis. Therefore, a critical issue for NK cell based therapy is the use of appropriate growth factors or cytokines that promote NK cell expansion and activation. We have previously shown that a murine GM-CSF/IL-2 fusion protein (aka GIFT2) displays novel antitumor properties in vivo compared to both cytokines in combination with regards to tumor site recruitment of significant functional NK cell infiltration. In the present work, we have generated the human counterpart of GIFT2 (hGIFT2). The functionality of both cytokines as part of the fusion protein was verified by performing proliferation assays in vitro with GM-CSF and IL-2 dependent cell lines (TF1 and CTLL-2 respectively). The effect of hGIFT2 on immune cells was analyzed by culturing PBMC with hGIFT2, as well as with both cytokines alone and in combination, and the number of immune cell types was quantified by flow cytometry. As result, hGIFT2 leads to a substantial four folds increase of human blood-derived NK cells which is significantly ($p<0.05$) superior to either IL2 or GM-CSF single cytokine treatment or both cytokines combined at equimolar concentrations. In addition, hGIFT2 induces robust expression of NK-cell activation markers: CD69 and CD107a as well as IFN gamma expression. As mechanism underlying hGIFT2 dependent effects, we determined that IL-2 and GM-CSF as part of the fusion act synergistically to induce greater activation of JAK/STAT and NF-kB pathways than single or combined cytokine treatment. Consequently, hGIFT2 induces significant expression of STAT5 and NF-kB target genes. In conclusion, the human hGIFT2 fusokine is a novel and potent tool for ex vivo expansion of activated NK cells which may be of use in cell-based immunotherapy of cancer.

**106** Poster

**Aerosoltherapy in lung cancer**

A. Maillet[1], L. Guilleminault[1], S. Pesnel[2], G. Paintaud[3], N. Congy-Jolivet[3], G. Thibault[3], S. Lerondel[2], E. Lemarié[1], N. Heuzé-Vourc'h[1]
*[1]Inserm U618, Université François Rabelais, Tours, France; [2] CNRS UPS44, Cdta, Orléans, France; [3] CNRS UMR 6239-GICC, Université François Rabelais, Tours, France*

Background: Although airways route might be an attractive alternative route to systemic administration, increasing concentration of the drug in the lungs while reducing whole-body toxicity, it is not often exploited for lung cancer treatment. In this study, we evaluated the nebulization of an anti-EGFR antibody (cetuximab) and established an animal model of broncho-pulmonary tumour sensitive to this antibody to compare the efficiency to target lung tumors and the pharmacokinetic of cetuximab through pulmonary and systemic routes.

Materials and methods: Cetuximab was nebulized with IA-1C MicroSprayer™ (PennCentury Inc., USA) connected to a FMJ-250 high pressure syringe, a device used to administrate, directly inside the trachea, aerosol in mice. The effect of nebulization on cetuximab was assessed in terms of its affinity for membrane EGFR (using flow cytometry), inhibition of cell growth and inhibition of EGFR phosphorylation. Then, tolerance to cetuximab delivered through airways was studied in mice without tumors. A model of lung cancer sensitive to cetuximab was established and consists in the instillation of human epidermoid carcinoma cells endotracheally in nude mice. Cetuximab was labelled either with a fluorescent dye or 64Cu and then, affinity to EGFR was evaluated in a competition assay by FACS. Optical imaging and microPET were used to follow biodistribution of labelled cetuximab administered through systemic or pulmonary routes in tumor-bearing animals. Blood samples were collected at different time point to analyze pharmacokinetic of cetuximab delivered through different routes.

Results: Firstly, our results showed that MicroSprayer™ did not alter cetuximab integrity, immunological and pharmacologic properties. Secondly, airway administration of cetuximab in mice seemed to be well-tolerated and did not induced additional toxicity in lungs, kidney, colon, skin, liver or spleen. Finally, FACS analysis demonstrated that labelled cetuximab displayed the same affinity to EGFR than the unmodified antibody. And higher, more rapid and prolonged tumor uptake was observed in animals receiving cetuximab through the pulmonary route.

Conclusions: These results highlight the potential of the pulmonary route for delivery of anticancer antibody in lung cancer.

**107** Poster

**Investigation of the potential of mesenchymal stem cells (MSCs) for gene delivery to breast tumours**

R.M. Dwyer[1], J.C. Morris[2], M. Murphy[3], F.P. Barry[3], T. O'Brien[3], M.J. Kerin[1]
*[1]National University of Ireland Galway, Department of Surgery, Galway, Ireland; [2] Mayo Clinic, Department of Endocrinology, Rochester, USA; [3] National University of Ireland Galway, Regenerative Medicine Institute, Galway, Ireland*

Background:The use of Mesenchymal Stem Cells (MSCs) as systemic delivery vehicles for therapeutic genes has been proposed as a result of their combined ability to home to the tumour site, and evade the host immune response. Previous studies from this laboratory and others have shown tumor specific migration and engraftment of MSCs, highlighting their potential role as delivery vehicles for therapeutic genes. The sodium iodide symporter (NIS) confers upon a cell the ability to concentrate iodide, and adenovirus mediated expression of this gene in cancer cells has previously been shown to permit imaging and subsequent ablation of transfected tumors using radiolabeled iodide. NIS expression in MSCs could potentially provide for noninvasive imaging of MSC migration and engraftment in vivo, and due to the pathlength of $^{131}I$, support ablation of surrounding tumor cells through bystander effect. The aim of this study was to establish membrane bound, functional expression of NIS in adult MSCs derived from healthy volunteers. Materials and Methods:MSCs were infected with an adenovirus containing NIS under the control of the CMV promoter. NIS gene expression was quantified using RQ-PCR, and protein expression and localization was detected by immuhistochemistry. The ability of transduced MSCs to concentrate iodide was determined at a variety of timepoints (1-10 days) following infection using radiolabelled iodide ($^{125}I$), with levels measured on a ÿ-counter. Potassium perchlorate ($KCLO_4$), a known inhibitor of NIS, was included in control wells. Results:There was an